LONDON, UK / ACCESSWIRE / April 23, 2018 / With the refocusing of the business and the new CEO's strategic review now implemented, e-Therapeutics (LSE: ETX) finds itself with the NDD platform and at least two lead preclinical small molecule immuno-oncology (I/O) assets at a time when big pharma partners are clamouring for those assets. This is because Merck and BMS's marketed anti-PD-1 antibodies need synergistic mechanisms to broaden and extend the number and duration of their responses. ETX's first partnership announcement will be a value inflection point.
We have updated our model for the FY18 results. With ETX’s active business development efforts now ratcheting-up, we have reviewed the recent early-stage I/O deals like Nektar's and Viralytics's Phase I transactions with Bristol Myers Squibb (BMS) and Merck & Co, respectively, We have also reviewed ten preclinical I/O licensing transactions. Adding one median preclinical I/O transaction to ETX's market capitalisation increases our valuation from $42m to £60m.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Andy Smith, +44 (0)20 3077 5700
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison
